BR0308293A - Terapia à base de estatina para aumentar a manutenção cognitiva - Google Patents
Terapia à base de estatina para aumentar a manutenção cognitivaInfo
- Publication number
- BR0308293A BR0308293A BR0308293-8A BR0308293A BR0308293A BR 0308293 A BR0308293 A BR 0308293A BR 0308293 A BR0308293 A BR 0308293A BR 0308293 A BR0308293 A BR 0308293A
- Authority
- BR
- Brazil
- Prior art keywords
- statin
- based therapy
- increase cognitive
- active ingredient
- galantamine
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title abstract 3
- 230000001149 cognitive effect Effects 0.000 title abstract 2
- 238000012423 maintenance Methods 0.000 title abstract 2
- 238000002560 therapeutic procedure Methods 0.000 title abstract 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229960003980 galantamine Drugs 0.000 abstract 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000026139 Memory disease Diseases 0.000 abstract 1
- 230000002596 correlated effect Effects 0.000 abstract 1
- -1 galantamine compound Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Abstract
"TERAPIA à BASE DE ESTATINA PARA AUMENTAR A MANUTENçãO COGNITIVA". A presente invenção refere-se a um método de tratamento de demência ou um distúrbio de memória, compreendendo a administração de uma quantidade terapeuticamente eficaz dos compostos de galantamina (I) e estatina (II). A invenção refere-se ainda a produtos que contêm como primeiro ingrediente ativo o composto de galantamina (I) e como segundo ingrediente ativo um composto de estatina (II), na forma de preparações combinadas para uso simultâneo, separado ou seq³encial, no tratamento de pacientes que sofrem de doença de Alzheimer ou de demências correlacionadas, e a composições farmacêuticas correlacionadas e seus usos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 | |
| PCT/EP2003/003324 WO2003082298A1 (en) | 2002-04-02 | 2003-03-28 | Statin therapy for enhancing cognitive maintenance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0308293A true BR0308293A (pt) | 2004-12-28 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0308293-8A BR0308293A (pt) | 2002-04-02 | 2003-03-28 | Terapia à base de estatina para aumentar a manutenção cognitiva |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (pt) |
| JP (1) | JP2005525391A (pt) |
| KR (1) | KR100986194B1 (pt) |
| CN (1) | CN100528164C (pt) |
| AT (1) | ATE331523T1 (pt) |
| AU (1) | AU2003226753B2 (pt) |
| BR (1) | BR0308293A (pt) |
| CA (1) | CA2480275C (pt) |
| CY (1) | CY1105545T1 (pt) |
| DE (1) | DE60306503T2 (pt) |
| DK (1) | DK1492539T3 (pt) |
| EA (1) | EA013069B1 (pt) |
| ES (1) | ES2268393T3 (pt) |
| HK (1) | HK1079688A1 (pt) |
| IL (2) | IL164317A0 (pt) |
| MX (1) | MXPA04009535A (pt) |
| NO (1) | NO20044698L (pt) |
| NZ (1) | NZ536111A (pt) |
| PL (1) | PL211160B1 (pt) |
| PT (1) | PT1492539E (pt) |
| UA (1) | UA79605C2 (pt) |
| WO (1) | WO2003082298A1 (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
| AU2005232447A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of Alzheimers disease |
| WO2005123068A2 (en) * | 2004-06-08 | 2005-12-29 | Axonyx, Inc. | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| US20160303146A1 (en) * | 2013-12-13 | 2016-10-20 | David A. TABACZYNSKI | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
-
2003
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en active IP Right Grant
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko active IP Right Grant
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2005
- 2005-12-21 HK HK05111808.4A patent/HK1079688A1/xx not_active IP Right Cessation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ536111A (en) | 2006-03-31 |
| CA2480275C (en) | 2011-08-16 |
| HK1079688A1 (en) | 2006-04-13 |
| CY1105545T1 (el) | 2010-07-28 |
| WO2003082298A1 (en) | 2003-10-09 |
| EP1492539B1 (en) | 2006-06-28 |
| JP2005525391A (ja) | 2005-08-25 |
| DE60306503T2 (de) | 2007-06-21 |
| MXPA04009535A (es) | 2005-01-25 |
| AU2003226753B2 (en) | 2007-06-28 |
| PT1492539E (pt) | 2006-11-30 |
| PL371551A1 (en) | 2005-06-27 |
| KR100986194B1 (ko) | 2010-10-07 |
| CN100528164C (zh) | 2009-08-19 |
| IL164317A (en) | 2010-04-29 |
| EA013069B1 (ru) | 2010-02-26 |
| CN1642555A (zh) | 2005-07-20 |
| EA200401295A1 (ru) | 2005-02-24 |
| KR20040096608A (ko) | 2004-11-16 |
| AU2003226753A1 (en) | 2003-10-13 |
| CA2480275A1 (en) | 2003-10-09 |
| ES2268393T3 (es) | 2007-03-16 |
| DK1492539T3 (da) | 2006-10-30 |
| ATE331523T1 (de) | 2006-07-15 |
| DE60306503D1 (de) | 2006-08-10 |
| IL164317A0 (en) | 2005-12-18 |
| NO20044698L (no) | 2004-10-29 |
| EP1492539A1 (en) | 2005-01-05 |
| UA79605C2 (en) | 2007-07-10 |
| PL211160B1 (pl) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| DE69713526D1 (de) | Lösliche prodrugs von paclitaxel | |
| EA200701296A1 (ru) | 3,5-дизамещенные и 3,5,7-тризамещенные 3h-оксазоло- и 3h-тиазоло[4,5-d] пиримидин-2-оны и их пролекарства | |
| BRPI0411255A (pt) | composto, composição farmacêutica, uso de um composto, métodos de tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| ATE361287T1 (de) | Neue indol-2-on derivate | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| RU94045155A (ru) | Способы ингибирования болезни альцгеймера | |
| LV12291A (lv) | Savienojums un farmaceitiskas kompozicijas ar triptazes aktivitates izmainam saistitu slimibu arstesanai | |
| BR0009043A (pt) | Composto, composição farmacêutica, e, método de tratar uma doença em um animal em que a atividade da cisteìna protease contribui para a patologia e/ou sintomatologia da doença | |
| BRPI0517481A (pt) | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica | |
| BR0210122A (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo | |
| ATE369355T1 (de) | Pyrimidinamid derivate und deren verwendung | |
| HUP0302635A2 (hu) | Valpronsav foszfolipidszármazékai és ezek keveréke | |
| ATE367387T1 (de) | Verwendung von oxindolderivaten zur behandlung von mit demenz in zusammenhang stehenden krankheiten, alzheimer-krankheit und mit glycogensynthasekinase-3 assoziierten leiden | |
| HUP0100539A2 (hu) | D-vitamint és kálciumot tartalmazó gyógyászati készítmények és eljárás azok előállítására | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| BRPI0409884A (pt) | compostos, composições farmacêuticas, método para o tratamento ou porfilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| BRPI0410654A (pt) | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| BR0116653A (pt) | Medicamento contendo uma poliamina como substância ativa | |
| ATE309803T1 (de) | Sphingomyelinase inhibitoren als wirkstoffe mit antiapoptotischer und antiseptischer wirkung | |
| BRPI0410657A (pt) | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| KR970005283A (ko) | 심근경색발생 후의 환자를 처치하기 위한 서트랄린의 용도 | |
| US20070141167A1 (en) | Use of Benzyl Nicotinate for Pain Relief | |
| RU98101105A (ru) | Новое применение в медицинских целях |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 13A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |